|Bid||43.05 x 900|
|Ask||45.92 x 800|
|Day's Range||44.83 - 46.00|
|52 Week Range||36.66 - 69.57|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2018 - Nov 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||73.20|
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Following a Recent Pre-New Drug Application Meeting with the FDA for UGN-101, the Company Has Concluded Patient Enrollment in the OLYMPUS Phase 3 Trial for Low-Grade Upper Tr
UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to the Company’s lead product candidate, UGN-101, (mitomycin gel) for instillation. UGN-101 is currently in Phase 3 development for the treatment of patients with low-grade upper tract urothelial cancer (LG UTUC). Breakthrough Therapy Designation is designed to expedite the development and review of new drugs to treat serious or life-threatening conditions, so patients may have access to therapies through FDA approval as soon as possible.
NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The big shareholder groups in UroGen Pharma Ltd (NASDAQ:URGN) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own Read More...
UroGen Pharma Ltd. , a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference in New York, NY on Tuesday, October 2, 2018 at 2:30PM Eastern Time.
UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company, today announced that Jones “Woody” Bryan, Ph.D. has been appointed as Senior Vice President of Business Development. Dr. Bryan is a seasoned industry veteran who brings to UroGen over 25 years of experience driving growth across organizations with his diverse track record of product and technology licensings and M&A negotiations and transactions. Dr. Bryan will focus on the integration of corporate strategy and business development to assess potential partnerships and bolster UroGen’s product portfolio.
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / UroGen Pharma Ltd. (NASDAQ: URGN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 8:30 AM Eastern Time. ...
UroGen Pharma Ltd’s (NASDAQ:URGN): UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The US$922.25M market-cap company announced a latest loss of -US$20.82MRead More...